Brokers Set Expectations for Opus Genetics FY2024 Earnings

Opus Genetics, Inc. (NASDAQ:IRD) – Investment analysts at HC Wainwright cut their FY2024 earnings per share estimates for Opus Genetics in a research note issued on Wednesday, November 13th. HC Wainwright analyst M. Caufield now anticipates that the company will earn ($1.22) per share for the year, down from their previous estimate of ($1.11). HC Wainwright has a “Buy” rating and a $8.00 price target on the stock. The consensus estimate for Opus Genetics’ current full-year earnings is ($1.11) per share. HC Wainwright also issued estimates for Opus Genetics’ Q4 2024 earnings at ($0.34) EPS, FY2025 earnings at ($1.03) EPS, FY2026 earnings at ($0.75) EPS, FY2027 earnings at ($0.53) EPS and FY2028 earnings at ($0.23) EPS.

Opus Genetics Stock Down 1.9 %

NASDAQ:IRD opened at $1.06 on Friday. Opus Genetics has a fifty-two week low of $1.06 and a fifty-two week high of $3.40.

Opus Genetics (NASDAQ:IRD) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.29) earnings per share for the quarter, topping the consensus estimate of ($0.30) by $0.01. Opus Genetics had a negative net margin of 324.45% and a negative return on equity of 63.65%. The business had revenue of $3.87 million for the quarter, compared to analyst estimates of $1.17 million.

About Opus Genetics

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc, formerly known as Ocuphire Pharma Inc, is based in Farmington Hills, Michigan.